US government agencies have questioned the legality of cannabidiol (CBD) – just as the industry is starting to see the benefits of increased public awareness.
Actions by both the US Food and Drug Administration (FDA) and the US Drug Enforcement Administration (DEA) have recently cast doubt on the future of CBD, according to speakers at the Marijuana Business Conference (MJBizCon) held May 9th–11th in New Orleans.
The situation is further complicated by the lack of clarity over the status of CBD, as some stakeholders classify it as a drug and others as a dietary supplement. Speakers at the conference also discussed a potential loophole that would allow CBD to be legally sold as a product derived from industrial hemp.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
All you need to know to succeed in the Chinese market
New exclusive report: E-cigarettes in China: market, regulation and outlook
Looking for market trends and commercial opportunities in one of the fastest-growing e-cigarette markets in the world? If you want to identify the latest trends developing in the Chinese e-cigarette market, and ensure that products and business activities are fully compliant with Chinese regulation, then this new report is for you!